Reinforcing effects of σ-receptor agonists in rats trained to self-administer cocaine

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 2, 2010, Pages 515-524

  Hiranita, Takato ^a   Soto, Paul L ^a   Tanda, Gianluigi ^a   Katz, Jonathan L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 1,3 BIS(2 METHYLPHENYL)GUANIDINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; BD 1063; COCAINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] 4 METHYLPIPERAZINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] N METHYL 2 (1 PYRROLIDINYL)ETHYLAMINE; OPIATE ANTAGONIST; SIGMA RECEPTOR LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG SELF ADMINISTRATION; DRUG TARGETING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; TREATMENT RESPONSE;

ANIMALS; COCAINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHYLAMINES; GUANIDINES; MALE; MORPHOLINES; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION;

EID: 76749142426     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.159236     Document Type: Article

References (40)

1. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, and Stephens DN (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology (Berl) 153:67-84.
2. Cao J, Kulkarni SS, Husbands SM, Bowen WD, Williams W, Kopajtic T, Katz JL, George C, and Newman AH (2003) Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. J Med Chem 46:2589-2598.
3. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, and Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptormediated behavior. J Pharmacol Exp Ther 314:310-319.
4. de Costa BR, Iadarola MJ, Rothman RB, Berman KF, George C, Newman AH, Mahboubi A, Jacobson AE, and Rice KC (1992) Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17- (cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinan. J Med Chem 35:2826-2835.
5. Gonzalez-Alvear GM and Werling LL (1994) Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther 271:212-219.
6. Hayashi T and Su TP (2001) Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci U S A 98:491-496.
7. Hayashi T and Su TP (2004) Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18:269-284.
8. Liu Y, Chen GD, Lerner MR, Brackett DJ, and Matsumoto RR (2005) Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J Pharmacol Exp Ther 314:770-779.
9. Liu Y and Matsumoto RR (2008) Alterations in fos-related antigen 2 and sigma1 receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: time course and regional distribution studies. J Pharmacol Exp Ther 327:187-195.
10. Martin-Fardon R, Maurice T, Aujla H, Bowen WD, and Weiss F (2007) Differential effects of sigma1 receptor blockade on self-administration and conditioned reinstatement motivated by cocaine vs natural reward. Neuropsychopharmacology 32:1967-1973.
11. Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, and De Costa BR (1995) Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol 280:301-310.
12. Matsumoto RR, Bowen WD, Walker JM, Patrick SL, Zambon AC, Vo VN, Truong DD, De Costa BR, and Rice KC (1996) Dissociation of the motor effects of (+)-pentazocine from binding to sigma 1 sites. Eur J Pharmacol 301:31-40.
13. Matsumoto RR, Hemstreet MK, Lai NL, Thurkauf A, De Costa BR, Rice KC, Hellewell SB, Bowen WD, and Walker JM (1990) Drug specificity of pharmacological dystonia. Pharmacol Biochem Behav 36:151-155.
14. Matsumoto RR, Liu Y, Lerner M, Howard EW, and Brackett DJ (2003) Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 469:1-12.
15. Matsumoto RR and Mack AL (2001) (+/-)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur J Pharmacol 417:R1-2.
16. Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, and Bowen WD (2001) Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol 419:163-174.
17. Maurice T, Martin-Fardon R, Romieu P, and Matsumoto RR (2002) Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 26:499-527.
18. Maurice T, Phan VL, Noda Y, Yamada K, Privat A, and Nabeshima T (1999) The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (sigma) receptor ligands involves both sigma1 and sigma2 sites. Br J Pharmacol 127:335-342.
19. Maurice T and Su TP (2009) The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195-206.
20. McCracken KA, Bowen WD, and Matsumoto RR (1999) Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur J Pharmacol 365:35-38.
21. Menkel M, Terry P, Pontecorvo M, Katz JL, and Witkin JM (1991) Selective sigma ligands block stimulant effects of cocaine. Eur J Pharmacol 201:251-252.
22. Nuwayhid SJ and Werling LL (2003) Sigma1 receptor agonist-mediated regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther 304:364-369.
23. Nuwayhid SJ and Werling LL (2006) Sigma2 (sigma2) receptors as a target for cocaine action in the rat striatum. Eur J Pharmacol 535:98-103.
24. Romieu P, Martin-Fardon R, and Maurice T (2000) Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. Neuroreport 11: 2885-2888.
25. Romieu P, Phan VL, Martin-Fardon R, and Maurice T (2002) Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 26:444-455.
26. Sabino V, Cottone P, Zhao Y, Iyer MR, Steardo L, Jr., Steardo L, Rice KC, Conti B, Koob GF, and Zorrilla EP (2009) The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking. Neuropsychopharmacology 34:1482-1493.
27. Sahu A, Tyeryar KR, Vongtau HO, Sibley DR, and Undieh AS (2009) D5 dopamine receptors are required for dopaminergic activation of phospholipase C. Mol Pharmacol 75:447-453.
28. Sharkey J, Glen KA, Wolfe S, and Kuhar MJ (1988) Cocaine binding at sigma receptors. Eur J Pharmacol 149:171-174.
29. Slifer BL and Balster RL (1983) Reinforcing properties of stereoisomers of the putative sigma agonists N-allylnormetazocine and cyclazocine in rhesus monkeys. J Pharmacol Exp Ther 225:522-528.
30. Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, and Su TP (2004) Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls. Psychopharmacology (Berl) 175:68-75.
31. Su TP (1993) Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol 7:187-203.
32. Su TP and Hayashi T (2001) Cocaine affects the dynamics of cytoskeletal proteins via sigma(1) receptors. Trends Pharmacol Sci 22:456-458.
33. Ujike H, Kanzaki A, Okumura K, Akiyama K, and Otsuki S (1992a) Sigma (sigma) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sci 50:PL129-PL134.
34. Ujike H, Kuroda S, and Otsuki S (1996) sigma Receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol 296:123-128.
35. Ujike H, Tsuchida K, Akiyama K, and Otsuki S (1992b) Supersensitivity of sigma receptors after repeated administration of cocaine. Life Sci 51:PL31-PL36.
36. Ukai M, Mori E, and Kameyama T (1997) Modulatory effects of morphine, U-50488H and 1,3-di-(2-tolyl)guanidine on cocaine-like discriminative stimulus in the rat using two-choice discrete-trial avoidance paradigm. Methods Find Exp Clin Pharmacol 19:541-546.
37. Undie AS, Berki AC, and Beardsley K (2000) Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways. Neuropharmacology 39:75-87.
38. Wachtel SR and White FJ (1988) Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. J Pharmacol Exp Ther 244:410-416.
39. Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, and Walker FO (1988) Evidence for a role of haloperidol-sensitive sigma-'opiate' receptors in the motor effects of antipsychotic drugs. Neurology 38:961-965.
40. Witkin JM, Terry P, Menkel M, Hickey P, Pontecorvo M, Ferkany J, and Katz JL (1993) Effects of the selective sigma receptor ligand, 6-[6-(4- hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther 266:473-482.